Luminex
This article was originally published in The Gray Sheet
Executive Summary
Agreement with Bayer Diagnostics allowing German firm to develop and distribute in vitro diagnostic tests based on Luminex' xMAP multi-analyte technology includes a multi-year deal for developing a new cellular analyzer. For the license agreement, Bayer will pay Luminex a one-time fee along with royalties once the tests are commercialized. Bayer will develop and sell the new flow cytometry analyzer for monitoring immunological status and blood disease, while Luminex will manufacture the product...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.